The Oxford Royal College of General Practitioners Clinical Informatics Digital Hub: Protocol to Develop Extended COVID-19 Surveillance and Trial Platforms.


Journal

JMIR public health and surveillance
ISSN: 2369-2960
Titre abrégé: JMIR Public Health Surveill
Pays: Canada
ID NLM: 101669345

Informations de publication

Date de publication:
02 07 2020
Historique:
received: 30 04 2020
accepted: 01 06 2020
revised: 29 05 2020
pubmed: 3 6 2020
medline: 8 7 2020
entrez: 3 6 2020
Statut: epublish

Résumé

Routinely recorded primary care data have been used for many years by sentinel networks for surveillance. More recently, real world data have been used for a wider range of research projects to support rapid, inexpensive clinical trials. Because the partial national lockdown in the United Kingdom due to the coronavirus disease (COVID-19) pandemic has resulted in decreasing community disease incidence, much larger numbers of general practices are needed to deliver effective COVID-19 surveillance and contribute to in-pandemic clinical trials. The aim of this protocol is to describe the rapid design and development of the Oxford Royal College of General Practitioners Clinical Informatics Digital Hub (ORCHID) and its first two platforms. The Surveillance Platform will provide extended primary care surveillance, while the Trials Platform is a streamlined clinical trials platform that will be integrated into routine primary care practice. We will apply the FAIR (Findable, Accessible, Interoperable, and Reusable) metadata principles to a new, integrated digital health hub that will extract routinely collected general practice electronic health data for use in clinical trials and provide enhanced communicable disease surveillance. The hub will be findable through membership in Health Data Research UK and European metadata repositories. Accessibility through an online application system will provide access to study-ready data sets or developed custom data sets. Interoperability will be facilitated by fixed linkage to other key sources such as Hospital Episodes Statistics and the Office of National Statistics using pseudonymized data. All semantic descriptors (ie, ontologies) and code used for analysis will be made available to accelerate analyses. We will also make data available using common data models, starting with the US Food and Drug Administration Sentinel and Observational Medical Outcomes Partnership approaches, to facilitate international studies. The Surveillance Platform will provide access to data for health protection and promotion work as authorized through agreements between Oxford, the Royal College of General Practitioners, and Public Health England. All studies using the Trials Platform will go through appropriate ethical and other regulatory approval processes. The hub will be a bottom-up, professionally led network that will provide benefits for member practices, our health service, and the population served. Data will only be used for SQUIRE (surveillance, quality improvement, research, and education) purposes. We have already received positive responses from practices, and the number of practices in the network has doubled to over 1150 since February 2020. COVID-19 surveillance has resulted in tripling of the number of virology sites to 293 (target 300), which has aided the collection of the largest ever weekly total of surveillance swabs in the United Kingdom as well as over 3000 severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) serology samples. Practices are recruiting to the PRINCIPLE (Platform Randomised trial of INterventions against COVID-19 In older PeopLE) trial, and these participants will be followed up through ORCHID. These initial outputs demonstrate the feasibility of ORCHID to provide an extended national digital health hub. ORCHID will provide equitable and innovative use of big data through a professionally led national primary care network and the application of FAIR principles. The secure data hub will host routinely collected general practice data linked to other key health care repositories for clinical trials and support enhanced in situ surveillance without always requiring large volume data extracts. ORCHID will support rapid data extraction, analysis, and dissemination with the aim of improving future research and development in general practice to positively impact patient care. DERR1-10.2196/19773.

Sections du résumé

BACKGROUND
Routinely recorded primary care data have been used for many years by sentinel networks for surveillance. More recently, real world data have been used for a wider range of research projects to support rapid, inexpensive clinical trials. Because the partial national lockdown in the United Kingdom due to the coronavirus disease (COVID-19) pandemic has resulted in decreasing community disease incidence, much larger numbers of general practices are needed to deliver effective COVID-19 surveillance and contribute to in-pandemic clinical trials.
OBJECTIVE
The aim of this protocol is to describe the rapid design and development of the Oxford Royal College of General Practitioners Clinical Informatics Digital Hub (ORCHID) and its first two platforms. The Surveillance Platform will provide extended primary care surveillance, while the Trials Platform is a streamlined clinical trials platform that will be integrated into routine primary care practice.
METHODS
We will apply the FAIR (Findable, Accessible, Interoperable, and Reusable) metadata principles to a new, integrated digital health hub that will extract routinely collected general practice electronic health data for use in clinical trials and provide enhanced communicable disease surveillance. The hub will be findable through membership in Health Data Research UK and European metadata repositories. Accessibility through an online application system will provide access to study-ready data sets or developed custom data sets. Interoperability will be facilitated by fixed linkage to other key sources such as Hospital Episodes Statistics and the Office of National Statistics using pseudonymized data. All semantic descriptors (ie, ontologies) and code used for analysis will be made available to accelerate analyses. We will also make data available using common data models, starting with the US Food and Drug Administration Sentinel and Observational Medical Outcomes Partnership approaches, to facilitate international studies. The Surveillance Platform will provide access to data for health protection and promotion work as authorized through agreements between Oxford, the Royal College of General Practitioners, and Public Health England. All studies using the Trials Platform will go through appropriate ethical and other regulatory approval processes.
RESULTS
The hub will be a bottom-up, professionally led network that will provide benefits for member practices, our health service, and the population served. Data will only be used for SQUIRE (surveillance, quality improvement, research, and education) purposes. We have already received positive responses from practices, and the number of practices in the network has doubled to over 1150 since February 2020. COVID-19 surveillance has resulted in tripling of the number of virology sites to 293 (target 300), which has aided the collection of the largest ever weekly total of surveillance swabs in the United Kingdom as well as over 3000 severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) serology samples. Practices are recruiting to the PRINCIPLE (Platform Randomised trial of INterventions against COVID-19 In older PeopLE) trial, and these participants will be followed up through ORCHID. These initial outputs demonstrate the feasibility of ORCHID to provide an extended national digital health hub.
CONCLUSIONS
ORCHID will provide equitable and innovative use of big data through a professionally led national primary care network and the application of FAIR principles. The secure data hub will host routinely collected general practice data linked to other key health care repositories for clinical trials and support enhanced in situ surveillance without always requiring large volume data extracts. ORCHID will support rapid data extraction, analysis, and dissemination with the aim of improving future research and development in general practice to positively impact patient care.
INTERNATIONAL REGISTERED REPORT IDENTIFIER (IRRID)
DERR1-10.2196/19773.

Identifiants

pubmed: 32484782
pii: v6i3e19773
doi: 10.2196/19773
pmc: PMC7333793
doi:

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

e19773

Informations de copyright

©Simon de Lusignan, Nicholas Jones, Jienchi Dorward, Rachel Byford, Harshana Liyanage, John Briggs, Filipa Ferreira, Oluwafunmi Akinyemi, Gayatri Amirthalingam, Chris Bates, Jamie Lopez Bernal, Gavin Dabrera, Alex Eavis, Alex J Elliot, Michael Feher, Else Krajenbrink, Uy Hoang, Gary Howsam, Jonathan Leach, Cecilia Okusi, Brian Nicholson, Philip Nieri, Julian Sherlock, Gillian Smith, Mark Thomas, Nicholas Thomas, Manasa Tripathy, William Victor, John Williams, Ian Wood, Maria Zambon, John Parry, Shaun O’Hanlon, Mark Joy, Chris Butler, Martin Marshall, FD Richard Hobbs. Originally published in JMIR Public Health and Surveillance (http://publichealth.jmir.org), 02.07.2020.

Références

BMJ. 2011 Mar 17;342:d1513
pubmed: 21415111
BMC Med Inform Decis Mak. 2011 Oct 13;11:61
pubmed: 21995837
Disabil Rehabil. 2012;34(19):1608-16
pubmed: 22489612
BMJ Open. 2016 Apr 20;6(4):e011092
pubmed: 27098827
Br J Gen Pract. 2017 Oct;67(663):440-441
pubmed: 28963401
Med Law Rev. 2015 Summer;23(3):348-74
pubmed: 25995294
Br J Gen Pract. 2017 Jan;67(654):e29-e40
pubmed: 27993900
JAMA. 2020 Apr 6;:
pubmed: 32250408
Circ Res. 2018 Apr 27;122(9):1290-1301
pubmed: 29700073
Int J Epidemiol. 2013 Dec;42(6):1608-13
pubmed: 24415602
Br J Gen Pract. 2010 Dec;60(581):e466-75
pubmed: 21144191
Int J Med Inform. 2007 Apr;76(4):261-8
pubmed: 16406791
Br J Gen Pract. 2018 Aug;68(673):362-363
pubmed: 30049755
Lancet. 2005 Mar 19-25;365(9464):1099-104
pubmed: 15781105
Qual Saf Health Care. 2008 Oct;17 Suppl 1:i3-9
pubmed: 18836063
Sci Data. 2016 Mar 15;3:160018
pubmed: 26978244
JMIR Res Protoc. 2019 Nov 11;8(11):e14186
pubmed: 31710303
J Law Med Ethics. 2019 Mar;47(1):12-20
pubmed: 30994067
Nat Rev Genet. 2018 Apr;19(4):208-219
pubmed: 29379135
Tech Innov Patient Support Radiat Oncol. 2017 Jun 27;2:5-12
pubmed: 32095558
PLoS One. 2016 Oct 18;11(10):e0164347
pubmed: 27755563
Comput Methods Programs Biomed. 2020 Jul;191:105409
pubmed: 32143073

Auteurs

Simon de Lusignan (S)

Nuffield Department of Primary Care Health Sciences, University of Oxford, Oxford, United Kingdom.
Royal College of General Practitioners, London, United Kingdom.

Nicholas Jones (N)

Nuffield Department of Primary Care Health Sciences, University of Oxford, Oxford, United Kingdom.

Jienchi Dorward (J)

Nuffield Department of Primary Care Health Sciences, University of Oxford, Oxford, United Kingdom.

Rachel Byford (R)

Nuffield Department of Primary Care Health Sciences, University of Oxford, Oxford, United Kingdom.

Harshana Liyanage (H)

Nuffield Department of Primary Care Health Sciences, University of Oxford, Oxford, United Kingdom.

John Briggs (J)

Nuffield Department of Primary Care Health Sciences, University of Oxford, Oxford, United Kingdom.

Filipa Ferreira (F)

Nuffield Department of Primary Care Health Sciences, University of Oxford, Oxford, United Kingdom.

Oluwafunmi Akinyemi (O)

Nuffield Department of Primary Care Health Sciences, University of Oxford, Oxford, United Kingdom.

Gayatri Amirthalingam (G)

Public Health England, London, United Kingdom.

Chris Bates (C)

TPP SystmOne, Leeds, United Kingdom.

Jamie Lopez Bernal (J)

Public Health England, London, United Kingdom.

Gavin Dabrera (G)

Public Health England, London, United Kingdom.

Alex Eavis (A)

EMIS Group, Leeds, United Kingdom.

Alex J Elliot (AJ)

Real-time Syndromic Surveillance Team, Field Service, Public Health England, Birmingham, United Kingdom.

Michael Feher (M)

Nuffield Department of Primary Care Health Sciences, University of Oxford, Oxford, United Kingdom.

Else Krajenbrink (E)

Royal College of General Practitioners, London, United Kingdom.

Uy Hoang (U)

Nuffield Department of Primary Care Health Sciences, University of Oxford, Oxford, United Kingdom.

Gary Howsam (G)

Royal College of General Practitioners, London, United Kingdom.

Jonathan Leach (J)

Royal College of General Practitioners, London, United Kingdom.

Cecilia Okusi (C)

Nuffield Department of Primary Care Health Sciences, University of Oxford, Oxford, United Kingdom.

Brian Nicholson (B)

Nuffield Department of Primary Care Health Sciences, University of Oxford, Oxford, United Kingdom.

Philip Nieri (P)

Nuffield Department of Primary Care Health Sciences, University of Oxford, Oxford, United Kingdom.

Julian Sherlock (J)

Nuffield Department of Primary Care Health Sciences, University of Oxford, Oxford, United Kingdom.

Gillian Smith (G)

Real-time Syndromic Surveillance Team, Field Service, Public Health England, Birmingham, United Kingdom.

Mark Thomas (M)

Royal College of General Practitioners, London, United Kingdom.

Nicholas Thomas (N)

Royal College of General Practitioners, London, United Kingdom.

Manasa Tripathy (M)

Nuffield Department of Primary Care Health Sciences, University of Oxford, Oxford, United Kingdom.

William Victor (W)

Royal College of General Practitioners, London, United Kingdom.

John Williams (J)

Nuffield Department of Primary Care Health Sciences, University of Oxford, Oxford, United Kingdom.

Ian Wood (I)

Royal College of General Practitioners, London, United Kingdom.
EMIS Group, Leeds, United Kingdom.

Maria Zambon (M)

Public Health England, London, United Kingdom.

John Parry (J)

TPP SystmOne, Leeds, United Kingdom.

Shaun O'Hanlon (S)

EMIS Group, Leeds, United Kingdom.

Mark Joy (M)

Nuffield Department of Primary Care Health Sciences, University of Oxford, Oxford, United Kingdom.

Chris Butler (C)

Nuffield Department of Primary Care Health Sciences, University of Oxford, Oxford, United Kingdom.

Martin Marshall (M)

Royal College of General Practitioners, London, United Kingdom.

F D Richard Hobbs (FDR)

Nuffield Department of Primary Care Health Sciences, University of Oxford, Oxford, United Kingdom.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH